NCT07476378 2026-03-17
Archonc-001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Not yet recruiting
Clinical Trials
11 trialsNCT07453095 2026-03-05
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Fondazione Italiana Linfomi - ETS
Phase 2 Not yet recruiting
NCT07412405 2026-02-17
ACITAC-001
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS
Phase NA Not yet recruiting
NCT07261163 2025-12-03
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07206264 2025-10-03
ADAPT-MCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07024147 2025-06-17
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Phase 1 Not yet recruiting
NCT06656221 2024-11-19
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06324994 2024-03-22
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
Dalian Medical University
Phase 2 Not yet recruiting
NCT06255704 2024-02-13
Z+RCHOP/RDHAP
Shanxi Province Cancer Hospital
Phase 2 Not yet recruiting
NCT04913103 2021-06-04
CLSGMCLPOLA
Czech Lymphoma Study Group
Phase 2 Not yet recruiting